Forget Neil Woodford! He should have stuck to buying great FTSE 100 stocks like these

The market today is ripe for Neil Woodford’s original, successful approach to investing, and we don’t have to make the mistakes that eventually toppled him.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Neil Woodford’s reputation as a shrewd stock picker is in tatters. And he pulled off that feat by switching investing styles, it seems.

He built his reputation during his 25 years at Invesco. There, he invested in mainly large companies. And he had a knack for getting the big calls right. For example, he avoided the worst effects of the 1990s dotcom bubble by steering clear of over-priced stocks. And he navigated the 2008 financial crisis by taking actions such as selling his holdings in bank shares some time before the stock market collapse.

Neil Woodford’s shrewd stock-picking

His big gains came from pouncing on shares in out-of-favour sectors such as tobacco. Then he held on to his stocks for a long time. Over around 20 years, the tobacco sector became the best-performing in the UK stock market. Indeed, shares such as British American Tobacco and Imperial Brands (Imperial Tobacco as it was back then) powered ahead, driven by powerful cash flow and rising dividends. The valuations up-rated over time, and previous low earnings multiples became chunky double-digit numbers.

Woodford repeated the trick with another defensive, cash-generating sector – pharmaceuticals. When everyone was worried about patent cliffs and falling earnings back in the mid-to-late noughties, he loaded up with stocks such as AstraZeneca and GlaxoSmithKline. The valuations were modest. Now, worries are fading and the valuations are rating higher – just like tobacco stocks did.

But Woodford didn’t stick to the strategy that brought him so much success. Instead, when he started up his own Woodford Investment Management company, he gradually ditched the big-caps and started buying smaller cyclical companies. But those firms had previously enjoyed several years of high earnings. And the valuation measures looked low, such as modest P/E ratings and high dividend yields.

Peter Lynch knew better!

It proved to be too early to head for the cyclicals, and many plunged after he bought them. Indeed, Peter Lynch cautioned against buying cyclicals under such conditions in his books One Up on Wall Street and Beating the Street. Lynch argued that the best time to buy cyclical shares is when earnings and share prices have plunged, and when valuations superficially look high when measured against lower profits.

Recently, the coronavirus pandemic has created the ‘right’ conditions for buying cyclical shares. Many are now springing up from their lows. For example, banks look attractive, along with housebuilders, retailers and others. Indeed, investing in cyclicals over the past few years looks like one of the big calls that Woodford got wrong.

But it wasn’t the only cause of his troubles in the markets. He started investing in speculative, often profitless ‘jam-tomorrow’ stocks with a great story. And few of those types of stocks tend to outperform over time. Yet Woodford really went for it and loaded up with many of them. But he had little obvious previous experience with that investing style.

My guess is Woodford could have achieved great results if he’d stuck to his original investing style of picking good-quality, defensive stocks when they are selling cheaply. The market is ripe for such an approach today, and we don’t have to make the mistakes that toppled Neil Woodford.

Kevin Godbold has no position in any share mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Imperial Brands. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Will the S&P 500 crash in 2026?

The S&P 500 delivered impressive gains in 2025, but valuations are now running high. Are US stocks stretched to breaking…

Read more »

Teenage boy is walking back from the shop with his grandparent. He is carrying the shopping bag and they are linking arms.
Investing Articles

How much do you need in a SIPP to generate a brilliant second income of £2,000 a month?

Harvey Jones crunches the numbers to show how investors can generate a high and rising passive income from a portfolio…

Read more »

Investing Articles

Will Lloyds shares rise 76% again in 2026?

What needs to go right for Lloyds shares to post another 76% rise? Our Foolish author dives into what might…

Read more »

Investing Articles

How much passive income will I get from investing £10,000 in an ISA for 10 years?

Harvey Jones shows how he plans to boost the amount of passive income he gets when he retires, from FTSE…

Read more »

Investing Articles

Down 34% in 2025 — but could this be one of the UK’s top growth stocks for 2026?

With clarity over research funding on the horizon, could Judges Scientific be one of the UK’s best growth stocks to…

Read more »

piggy bank, searching with binoculars
Investing Articles

Can the rampant Barclays share price beat Lloyds in 2026?

Harvey Jones says the Barclays share price was neck and neck with Lloyds over the last year, and checks out…

Read more »

Investing Articles

Here’s how Rolls-Royce shares could hit £25 in 2026

If Rolls-Royce shares continue their recent performance, then £25 might be on the cards for 2026. Let's take a look…

Read more »

Departure & Arrival sign, representing selling and buying in a portfolio
Investing Articles

Prediction: in 2026 the red-hot Rolls-Royce share price could turn £10,000 into…

Harvey Jones can't believe how rapidlly the Rolls-Royce share price has climbed. Now he looks at the FTSE 100 growth…

Read more »